They then confirmed the involvement of GRP78 and the UPR in regulating the survival of mut-BRAF CRC cells by using HA15, a small molecule inhibitor against GRP78 that has been previously reported to display anti-cancerous activity on melanoma cells, including cells isolated from patients and cells that developed resistance to BRAF inhibitors, and other liquid and solid tumors. The gene discussed is BRAF; the disease is colorectal carcinoma.